Molecular genetics of prostate cancer: Clinical translational opportunities

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 1, 2007, Pages 25-37

  Vecchione, A ^a   Gottardo, F ^a,b   Gomella, L G ^a   Wildemore, B ^a   Fassan, M ^a,b   Bragantini, E ^a   Pagano, F ^b   Baffa, Raffaele ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

LOH; Molecular alterations; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACETYLSALICYLIC ACID; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P16INK4A; PROTEIN P53; RAF PROTEIN; SOMATOMEDIN; TELOMERASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

AGING; ANDROGEN ABLATION THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 17P; CHROMOSOME MUTATION; CLINICAL TRIAL; FATTY ACID METABOLISM; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; META ANALYSIS; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; PEDIGREE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247495122     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Gronberg H.: Prostate cancer epidemiology. Lancet 361:859-864, 2003.
2. Jemal A., Siegel R., Ward E. et al: Cancer statistics, 2006. CA. Cancer. J. Clin. 56:106-130, 2006.
3. De Marzo A.M., Nelson W.G., Isaacs W.B., Epstein J.I.: Pathological and molecular aspects of prostate cancer. Lancet 361:955-964, 2003.
4. Kopper L., Timar J.: Genomics of prostate cancer: is there anything to "translate"α Pathol. Oncol. Res. 11:197-203, 2005.
5. Mimeault M., Batra S.K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27:1-22, 2006.
6. Harden S.V., Guo Z., Epstein J.I., Sidransky D.: Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol. 169:1138-1142, 2003.
7. Bastian P.J., Palapattu G.S., Lin X. et al: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Cancer Res. 65:4762-8, 2005.
8. Van de Sande T., Roskams T., Lerut E. et al: High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol. 206:214-219, 2005.
9. Mubiru J.N., Valente A.J., Troyer D.A.: A Variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Prostate 65:117-123, 2005.
10. Gayther S.A., de Foy K.A., Harrington P. et al: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res. 60:4513-4518, 2000.
11. Edwards S.M., Kote-Jarai Z., Meitz J. et al: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72:1-12, 2003.
12. Liede A., Karlan B.Y., Narod S.A.: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2. J. Clin. Oncol. 22:735-742, 2004.
13. Smith J.R., Freije D., Carpten J.D. et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374, 1996.
14. Tavtigian S.V., Simard J., Teng D.H. et al: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 27:172-180, 2001.
15. Rennert H., Zeigler-Johnson C.M., Addya K. et al: Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol. Biomarkers Prev. 14:949-957, 2005.
16. Carpten J., Nupponen N., Issacs S. et al.: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30:181-184, 2002.
17. Xu J., Zheng S.L., Komiya A. et al: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat. Genet. 32: 321-325, 2002.
18. Korver W., Guevara C., Chen Y. et al: The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex. Int. J. Cancer 104: 283-288, 2003.
19. Suarez B.K., Gerhard D.S., Lin J. et al: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res. 61:4982-4984, 2001.
20. Rokman A., Ikonen T., Mononen N. et al: ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 61:6038-6041, 2001.
21. Wang L., McDonnell S.K., Elkins D.A. et al: Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 61:6494-6499, 2001.
22. De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G.: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155:1985-1992, 1999.
23. Malathi K., Paranjape J.M., Bulanova E., et al.: A transcriptional signaling pathway in the IFN system mediated by 2′-5′-oligoadenylate activation of RNase L.Proc. Natl. Acad. Sci. U. S. A. 102:14533-14538, 2005.
24. Rennert H, Bercovich D, Hubert A. et al: A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am. J. Hum. Genet. 71:981-984, 2002.
25. Rokman A., Ikonen T., Seppala E.H. et al: Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70:1299-1304, 2002.
26. Ross R.K., Bernstein L., Lobo R.A. et al: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887-889, 1992.
27. Reichardt J.K., Makridakis N., Henderson B.E., Yu M.C., Pike M.C., Ross R.K.: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 55:3973-3975, 1995.
28. Makridakis N.M., Ross R.K., Pike M.C.: Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978, 1999.
29. Lunn R.M., Bell D.A., Mohler J.L., Taylor J.A.: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 20:1727-1731, 1999.
30. Gsur A., Bernhofer G., Hinteregger S. et al: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer 87:434-437, 2000.
31. Yamada Y., Watanabe M., Murata M. et al: Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer. 92:683-686, 2001.
32. Sakr W.A., Macoska J.A., Benson P. et al: Allelic loss in locally metastatic, multi sampled prostate cancer. Cancer Res. 54:3273-3277, 1994.
33. Qian J., Bostwick D.G., Takahashi S. et al: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 55:5408-5414, 1995.
34. Haggman M.J., Wojno K.J., Pearsall C.P., Macoska J.A.: Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology 50:643-647, 1997b.
35. Nagle R.B., Brawer M.K., Kittelson J., Clark V.: Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am. J. Pathol. 138: 119-128, 1991.
36. Haggman M.J., Macoska J.A., Wojno K.J., Oesterling J.E.: The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues. J. Urol. 158:12-22, 1997a.
37. Chang M., Tsuchiya K., Batchelor R.H. et al: Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulcerative colitis, prostatic carcinoma, and malignant fibrous histiocytomas. Am. J. Pathol. 144: 1-6, 1994.
38. Matsuyama H., Pan Y., Skoog L. et al: Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 9: 3071-3076, 1994.
39. Macoska J.A., Trybus T.M., Benson P.D. et al: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 55: 5390-5395, 1995.
40. Vocke C.D., Pozzatti R.O., Bostwick D.G. et al: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56:2411-2416, 1996.
41. Macoska J.A., Trybus T.M., Wojno K.J.: 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 55:776-782, 2000.
42. van Duin M., van Marion R., Vissers K. et al: High-resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:438-449, 2005.
43. Bookstein R., Bova G.S., MacGrogan D., Levy A., Isaacs W.B.: Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Br. J. Urol. 79:28-36, 1997.
44. Cabeza-Arvelaiz Y., Sepulveda J.L., Lebovitz R.M., Thompson T.C., Chinault A.C.: Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20:4169-4179, 2001.
45. Chaib H., MacDonald J.W., Vessella R.L. et al: Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer 37:306-313, 2003.
46. He W.W., Sciavolino P.J., Wing J.: A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43:69-77, 1997.
47. Voeller H.J., Augustus M., Madike V., Bova G.S., Carter K.C., Gelmann E.P.: Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57:4455-4459, 1997.
48. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J. et al: Roles for Nkx3.1 in prostate development and cancer. Genes & Dev. 13: 966-977, 1999.
49. Abate-Shen C., Shen M.M.: Molecular genetics of prostate cancer. Genes & Dev. 14:2410-2434, 2000.
50. Cher M.L., Bova G.S., Moore D.H. et al: Genetic alterations in untreated metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56:3091-3102, 1996.
51. Melamed J., Einhorn J.M., Ittmann M.M. Allelic loss on chromosome 13q in human prostate carcinoma. Clin. Cancer Res. 3:1867-1872, 1997.
52. Kibel A. S., Schutte M., Kern S. E., Isaacs W. B., Bova G. S.: Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res. 58:5652-5655, 1998.
53. Brothman A. R., Maxwell T. M., Cui J., Deubler D. A., Zhu, X. L.: Chromosomal clues to the development of prostate tumors. Prostate 38:303-312, 1999.
54. Saric T., Brkanac Z., Troyer D.A. et al: Genetic pattern of prostate cancer progression. Int. J. Cancer 81: 219-224, 1999.
55. Verma R.S., Manikal M., Conte R.A., Godec C.J.: Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest. 17: 441-447, 1999.
56. van Dekken H., Alers J.C., Damen I.A. et al: Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and non-progressors. Lab. Invest. 83:789-796, 2003.
57. Miyoshi Y., Uemura H., Fujinami K. et al: Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43:225-232, 2000.
58. Carter B.S., Ewing C.M., Ward W.S. et al: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. 87: 8751-8755, 1990b.
59. Gray I.C., Phillips S.M., Lee S.J., Neoptolemos J.P., Weissenbach J., Spurr N.K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 55: 4800-4803, 1995.
60. Ittmann M.M.: Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res. 56: 2143-2147, 1996.
61. Trybus T.M., Burgess A.C., Wojno K.J., Glover T.W., Macoska J.A. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res. 56:2263-2267, 1996.
62. Steck P.A., Pershouse M.A., Jasser S.A. et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362, 1997.
63. Li J., Yen C., Liaw D. et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997.
64. Ali I.U., Schriml L.M., Dean M.: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91:1922-1932, 1999.
65. Rubin M.A., Gerstein A., Reid K. et al: 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2- 3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum. Pathol. 31:504-508, 2000.
66. Shaffer D.R., Scher H.I.: Prostate cancer: a dynamic illness with shifting targets. Lancet 4:407-414, 2003.
67. Elo J.P., Harkonen P., Kyllonen A.P., Lukkarinen O., Vihko P.: Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br. J. Cancer 79:156-160, 1999.
68. Elo J.P., Harkonen P., Kyllonen A.P. et al: Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 57: 3356-3359, 1997.
69. Macoska J.A., Powell I.J., Sakr W., Lane M.A.: Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J. Urol. 147:1142-1146, 1992.
70. Ittmann M.M.: Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 28:275-281, 1996.
71. Gumerlock P.H., Chi S.G., Shi X.B. et al: p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J. Natl. Cancer Inst. 89:66-71, 1997.
72. Brooks J.D., Bova G.S., Ewing C.M. et al: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56: 3814-3822, 1998.
73. Nastiuk K.L., Mansukhani M., Terry M.B. et al: Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40:172-177, 1999.
74. Cooney K.A., Wetzel J.C., Merajver S.D., Macoska J.A., Singleton T.P., Wojno K.J.: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res. 56:1142-1145, 1996b.
75. Li C., Larsson C., Futreal A. et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 16:481-487, 1998.
76. Dong J.T., Chen C., Stultz B.G., Isaacs J.T., Frierson H.F.: Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res. 60:3880-3883, 2000.
77. Zhao X., Gschwend J.E., Powell C.T., Foster R.G., Day K.C., Day M.L.: Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. J. Biol. Chem. 272:22751-22757, 1997.
78. Leite K.R., Franco M.F., Srougi M. et al: Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 14:428-436, 2001.
79. Zhang Z., Li M., Wang H., Agrawal S., Zhang R.: Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci.USA 100:11636-11641, 2003.
80. Latil A., Bieche I., Fournier G., Cussenot O., Pesche S., Lidereau R.: Molecular analysis of the FHIT gene in human prostate cancer. Oncogene 16:1863-1868, 1998.
81. Guo Z., Johansson S.L., Rhim J.S., Vishwanatha J.K.: Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. Prostate. 43:101-110, 2000.
82. Fouts R.L., Sandusky G.E., Zhang S., et al: Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer 97:1447-1452, 2003.
83. Berges R.R., Vukanovic J., Epstein J.I. et al: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1:473-480, 1995.
84. Tsihlias J., Kapusta L., Slingerland J.: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401-423, 1999.
85. Macri E., Loda M.: Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 17:337-344, 1999.
86. Guo Y., Sklar G.N., Borkowski A., Kyprianou N.: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 3:2269-2274, 1997.
87. Cote R.J., Shi Y., Groshen S., et al: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. 90: 916-920, 1998.
88. De Marzo A.M., Meeker A.K., Epstein J.I., Coffey D.S.: Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 153:911-919, 1998a.
89. Yang R.M., Naitoh J., Murphy M. et al: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159:941-945, 1998.
90. Cordon-Cardo C., Koff A., Drobnjak et al: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 90:1284-1291, 1998.
91. Chi S.G., deVere White R.W., Muenzer J.T., Gumerlock P.H.: Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res. 3:1889-1897, 1997.
92. Chen W., Weghorst C.M., Sabourin C.L. et al: Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 17:2603-2607, 1996.
93. Tamimi Y., Bringuier P.P., Smit F., van Bokhoven A., Debruyne F.M., Schalken J.A.: p 16 mutations/deletions are not frequent events in prostate cancer. Brit. J. Cancer 74: 120-122, 1996.
94. Gaddipati J.P., McLeod D.G., Sesterhenn I.A. et al: Mutations of the p16 gene product are rare in prostate cancer. Prostate 30:188-194, 1997.
95. Mangold K.A., Takahashi H., Brandigi C. et al: p16 (CD-KN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. J. Urol. 157:1117-1120, 1997.
96. Halvorsen O.J., Hostmark J., Haukaas S., Hoisaeter P.A., Akslen L.A.: Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88:416-424, 2000.
97. Lee C.T., Capodieci P., Osman I. et al: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res. 5: 977-983, 1999.
98. Olapade-Olaopa E.O., Moscatello D.K., MacKay E.H. et al: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer 82:186-194, 2000.
99. Ross J.S., Sheehan C., Hayner-Buchan A.M. et al: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol. 28:827-833, 1997.
100. Ross J.S., Sheehan C.E., Hayner-Buchan A.M. et al: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79:2162-2170, 1997.
101. Sommerfeld H.J., Meeker A.K., Piatyszek M.A., Bova G.S., Shay J.W., Coffey D.S.: Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res. 56: 218-222, 1996.
102. Zhang W., Kapusta L.R., Slingerland J.M., Klotz L.H.: Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58:619-621, 1998.
103. De Miguel P., Royuela M., Bethencourt R., Ruiz A., Fraile B., Paniagua R.: Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11:722-727, 1999.
104. Rubenstein M., Slobodskoy L., Mirochnik Y., Guinan P.: Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines. Methods Find. Exp. Clin. Pharmacol. 24:649-652, 2002.
105. Cardillo M. R., Petrangeli E., Perracchio L., Salvatori L., Ravenna L., Di Silverio F.: Transforming growth factor-beta expression in prostate neoplasia. Anal. Quant. Cytol. Histol. 22:1-10, 2000.
106. Kim I.Y., Ahn H.J., Zelner D.J., et al: Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2:1255-1261, 1996.
107. Peehl D.M., Cohen P., Rosenfeld R.G.: The insulin-like growth factor system in the prostate. World J. Urol. 13:306-311, 1995.
108. Pollak M., Beamer W., Zhang J.C.: Insulin-like growth factors and prostate cancer, Cancer Metastasis Rev. 17:383-390, 1998.
109. Figueroa J.A., De Raad S., Tadlock L., Speights V.O., Rinehart J.J.: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol. 159:1379-1383, 1998.
110. Chan J.M., Stampfer M.J., Giovannucci E. et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566, 1998.
111. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R.: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1102-1106, 1993.
112. Kimura G., Kasuya J., Giannini S. et al: Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol. 3:39-46, 1996.
113. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., Murphy G.P.: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127-133, 1999.
114. Nakashima J., Tachibana M., Horiguchi Y. et al: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6:2702-2706, 2000.
115. Roberts R.O., Jacobson D.J., Girman C.J. et al: A population-based study of daily non steroidal anti inflammatory drug use and prostate cancer. Mayo Clin. Proc. 77:219-225, 2002.
116. Zha S., Gage W.R., Sauvageot J. et al: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61:8617-8623, 2001.
117. Liu X.H., Yao S., Kirschenbaum A., Levine A.C.: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:4245-4249, 1998.
118. Yoshimura R., Sano H., Masuda C. et al: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89:589-596, 2000.
119. Madaan S., Abel P.D., Chaudhary K.S., Hewitt R., Stott M.A., Stamp G.W., Lalani E.N.: Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86:736-741, 2000.
120. Lee L.M., Pan C.C., Cheng C.J., Chi C.W., Liu T.Y.: Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 21:1291-1294, 2001.
121. Pruthi R.S., Derksen E., Gaston K.: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J. Urol. 169:2352-2359, 2003.
122. Uotila P., Valve E., Martikainen P., Nevalainen M., Nurmi M., and Harkonen P.: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 29:23-28, 2001.
123. Kamijo T., Sato T., Nagatomi Y., Kitamura T.: Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int. J. Urol. 8:S35-39, 2001.
124. Cornford P.A., Dodson A.R., Parsons K.F., et al: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60:7099-7105, 2000.
125. Gibbons N.B., Watson R.W., Coffey R.N., Brady H.P., Fitzpatrick J.M.: Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45:58-65, 2000.
126. Lebret T., Watson R.W., Fitzpatrick J.M.: Heat shock proteins: their role in urological tumors. J. Urol. 169:338-346, 2003.
127. Georget V., Terouanne B., Nicolas J.C., Sultan C.: Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824-11831, 2002.
128. Pizer E.S., Pflug B.R., Bova G.S., Han W.F., Udan M.S., Nelson J.B.: Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47:102-110, 2001.
129. Swinnen J.V., Roskams T., Joniau S., et al: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer 98:19-22, 2002.
130. Rubin M.A., Zhou M., Dhanasekaran S.M., et al: alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662-1670, 2002.
131. Luo J., Zha S., Gage W.R., et al: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62:2220-2226, 2002.
132. Lee W.H., Isaacs W.B., Bova G.S., Nelson W.G.: CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6:443-450, 1997.
133. Bentel J.M., Tilley W.D.: Androgen receptors in prostate cancer. J. Endocrinol. 151:1-11, 1996.
134. Culig Z., Hobisch A., Hittmair A., et al: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35: 63-70, 1998.
135. Koivisto P., Kolmer M., Visakorpi T., Kallioniemi O.P.: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152: 1-9, 1998.
136. Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.J.: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50: 5382-5386, 1990.
137. Taplin M.E., Bubley G.J., Shuster T.D., et al: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:1393-1398, 1995.
138. Marcelli M., Ittmann M., Mariani S. et al: Androgen receptor mutations in prostate cancer. Cancer Res. 60:944-949, 2000.
139. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A. et al: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Intl. J. Cancer 48: 189-193, 1991.
140. Ruizeveld de Winter J.A., Janssen P.J., Sleddens H.M. et al: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144:735-746, 1994.
141. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A.: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55: 3068-3072, 1995.
142. Sweat S.D., Pacelli A., Bergstralh E.J., Slezak J.M., Bostwick D.G.: Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J. Urol. 161:1229- 1232, 1999.
143. Kinoshita M., Nakagawa T., Shimizu A., Katsuoka Y.: Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int. J. Urol. 12:390-397, 2005.
144. Edwards J., Krishna N.S., Witton C.J., Bartlett J.M.S.: Gene amplifications associated with the development of hormone resistant prostate cancer. Clin. Cancer Res. 9:2571-2581, 2003.
145. Bernard D., Pourtier-Manzanedo A., Gil J., Beach D.H.: Myc confers androgen-independent prostate cancer cell growth. J. Clin. Invest. 112:1724-1731, 2003.
146. Lara P.N., Meyers F.J., Gray C.R. et al: Her-2/neu is overex-pressed infrequently in patients with prostate carcinoma. Cancer 94:2584-2589, 2002.
147. Lorenzo G.D., Bianco R., Torora G., Ciardillo F.: Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin. Prostate Cancer 2:50-57, 2003.
148. Apakama I., Robinson M.C., Walter N.M. et al: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Brit. J. Cancer 74:1258-1262, 1996.
149. Gregory C.W., Fei X., Ponguta L., et al: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 179:7119-7130, 2004
150. Dinjens W.N., van der Weiden M.M., Schroeder F.H., Bosman F.T., Trapman J.: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer 56:630-3, 1994.
151. Colombel M., Symmans E, Gil S., et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143: 390-400, 1993.
152. Furuya Y., Krajewski S., Epstein J.I., Reed J.C., Isaacs J.T.: Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2: 389-398, 1996.
153. Krajewska M., Krajewski S., Epstein J.I., et al: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148:1567-1576, 1996.
154. McDonnell T.J., Navone N.M., Troncoso P. et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. 157:569-574, 1997.
155. Chia S. J., Tang W. Y., Elnatan J., Yap W. M., Goh H. S., Smith, D. R.: Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br. J. Cancer. 83:761-768, 2000.
156. Dong J.T., Lamb P.W., Rinker-Schaeffer C. W., et al: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886, 1995.
157. Jackson P., Millar D., Kingsley E. et al: Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines Cancer Lett. 157: 169-176, 2000.
158. Paul R., Ewing C.M., Jarrard D.F., Isaacs W.B. The cadherin cell-cell adhesion pathway in prostate cancer progression. Br. J. Urol. 79:37-43, 1997.
159. Tomita K., van Bokhoven A., van Leenders G.J. et al: Cadherin switching in human prostate cancer progression. Cancer Res. 60:3650-3654, 2000.
160. Lindstrom S., Wiklund F., Jonsson B.A. et al: Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum. Genet. 28:1-9, 2005.
161. Singal R., Ferdinand L., Reis I.M., Schlesselman J.J.: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol. Rep. 12:631-637, 2004.
162. Nagabhushan M., Pretlow T.G., Guo Y.J., Amini S.B., Pretlow T.P., Sy M.S.: Altered expression of CD44 in human prostate cancer during progression. Am. J. Clin. Pathol. 106:647-651, 1996.
163. Noordzij M.A., van Steenbrugge G.J., Verkaik N.S., Schroder F.H., van der Kwast T.H.: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin. Cancer Res. 3:805-815, 1997.
164. De Marzo A.M., Bradshaw C., Sauvageot J., Epstein J.I., Miller G.J.: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34:162-168, 1998.
165. Kallakury B.V., Sheehan C.E., Ambros R.A. et al: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J. Clin. Oncol. 16:1302-1309, 1998.
166. Takahashi S., Kimoto N., Orita S., Cui L., Sakakibara M., Shirai T.: Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett. 129:97-102, 1998.
167. Thompson T.C.: Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev. 17:439-442, 1998.
168. Yang G., Truong L.D., Timme T.L. et al: Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4:1873-1880, 1998.
169. Haeusler J., Hoegel J., Bachmann N., et al: Association of a CAV-1 haplotype to familial aggressive prostate cancer. Prostate 63:369-84, 2005.
170. Yang G., Truong L.D., Wheeler T.M., Thompson T.C.: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59:5719-5723, 1999.
171. Tahir S.A., Ren C., Timme T.L. et al: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin. Cancer Res. 9:3653-3659, 2003.